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A New Series of Vitamin D Analogs Is Highly Active for Clonal Inhibition, Differentiation, and Induction of WAFl in Myeloid Leukemia
By Reinhold Munker, Tohru Kobayashi, Elena Elstner, Anthony W. Norman, Milan Uskokovic, Wei Zhang, Michael Andreeff, and H. Phillip Koeffler The active form of vitamin D3 [la,25-dihydroxyvitamin-D3 (la,25(OH)2D3)1 modulates the proliferation and differentiation of hematopoietic cells. Analogs of la,25(OH)2D3 that have greater potency may have the potential as adjuvant therapy for high-risk patients in remission for acute myelogenous leukemia (AML) and myelodysplastic syndromes. A new generation of 11 analogs of la,25(OH)2D3 has been synthesized, and we examined their effects on the human leukemic cell line HL-60. This cell line provides a sensitive monitor of activity of the la,25(OH)& analogs. All the compounds were potent, producing a 50% clonal inhibition ( ED, ) in the range of IO-'to 10"l mol/L; nine of the 11 analogs had EDsos at concentrations that were at least IO-fold lower than those for the parental 1,25(0H)2D3. The most active compound [cmpd L A , (22R)-1a,Z5-(OH)z-16,22,23-triene-D31 had an EDso of 2 x IO-" mol/L; it was also tested on clonogenic cells from patients with AML, and it achieved an E D , of approximately 6 x IO-" mol/L, while ltxu. 25 , results from sequential hydroxylations in the liver and kidney and is responsible for calcium homeostasis in the body. Vitamin D, metabolites have an important role for the proliferation of hematopoietic cells, lymphocytes, and keratinocytes, as well as other cell types.' The response to vitamin D, metabolites involves the nuclear receptor for la,25(OH)2D3, but direct effects also can occur through the cell membrane.' These latter effects may be mediated by G proteins, a Ca" gradient, and protein kinase C.'., Previously, we have characterized the interaction of 1,25(OH)2D3 with normal and leukemic hematopoietic cells. 4 Normal colony-forming cells were moderately stimulated in their proliferation by 1~, 2 5 ( 0 H )~D~, whereas leukemic cell lines with a mature phenotype were induced to differentiate and inhibited in their clonal
We and others have focused on the development of analogs of la,25(OH)zD3 that induce differentiation and inhibited proliferation of leukemic cells and yet possess diminished capacity to cause hyper~alcemia.~"' A clinical trial of 1,25(OH)'D3 in myelodysplastic syndromes did not normalize hematopoiesis; however, this trial was hindered by the low serum level of 1,25(OH)2D3 that was obtained before hypercalcemia developed.18 The structural features of prior analogs that enhanced antileukemic activity included a double bond at C-16, triple bond at C-23, substitution with fluorines at C-26 and C-27, and 20-epi-side-chain modification.' With these as lead structural motifs, we have synthesized analogs that contain two or more of these elements using HL-60 cells as a target and have examined the analogs' abilities to inhibit clonal growth, induce differentiation and activation-related cell surface antigens, and enhance expression of the cyclin-dependent kinase inhibitor (CDKI) known as WAFI/CIPl/p21. In addition, these results were compared Blood, Vol 88, No 6 (September 15), 1996: pp 2201-2209 DR and CD1 1 b were induced by all of the compounds; CD13 was induced by six of the 12 compounds, including 1,25(OH)2D3; CD14 was strongly induced by all compounds; and CD38 was induced rather weakly by nine of 12 analogs. WAFI/CIPl/p21, a cyclin-dependent kinase inhibitor (CDKI), which is important in blocking the cell cycle, was examined by Western blot and was found t o be induced by all of the compounds, suggesting a possible mechanism by which these analogs inhibit leukemic growth. The induction of WAFl occurred a t concentrations of vitamin D analogs as low as mol/L. This structure-function study showed that a new series of 1a25(OH)2D3 analogs was active in clonal inhibition, as well as induction of differentiation and WAF1 expression of HL-60 cells. The key structural motifs included C-l6 double bond, double and/or triple bonds in the side chain, lengthening of the side chain, 20-epi-conformation of the side chain, replacement of six hydrogens at the end of the side chain with fluorines, and the removal of C-19. Consideration should be given t o further in vivo testing of toxicity and efficacy t o move toward a clinical trial, especially in a setting of minimal residual disease. 0 1996 by The American Society of Hematology.
consent. The percentage of circulating blast cells was greater than 98%. Blood and bone marrow were anticoagulated by addition of preservative-free heparin (Sigma). Mononuclear cells from normal bone marrow and peripheral blood were collected by separation on Ficoll-Paque (Pharmacia, Piscataway, NJ) gradients at a density of 1.077, washed twice in phosphate-buffered saline, and suspended in IMDM containing 20% heat-inactivated fetal bovine serum (GIBCO).
1a,25(OH),D3 analogs. The parental compound [la,25(OH),D3] and the analogs were dissolved in absolute ethanol at 10" molL and stored at -20°C. The concentrations of the analogs were determined via UV absorbance measurements using their molar extinction coefficient at 264 nmol/L. Dilutions were made in the same tissue culture medium used for the growing of HL-60 cells. All manipulations with vitamin D analogs were performed protected from light. The maximal concentration of ethanol used in this study had no influence on cell growth. The simplified code names and structures of the la,25(OH)2D3 analogs, as well those of a previously studied compound (EO)," are shown in Fig 1. Colony formation in soft agar. HL-60 cells, which were greater than 99% viable, were seeded in a two-layer soft agar system as previously described? The lower layer consisted of 0.5% agar in which the test substances were mixed; the upper layer was 0.3% agar (Difco Laboratories, Detroit, MI) in which 1.000 HL-60 cells were mixed per plate. All experimental points were performed in triplicate. All plating experiments were repeated at least twice. The blast cells from three AML patients were cultured in IMDM, 20% FCS, 10% phytohemagglutinin-leukocyte-conditioned medium (PHA-LCM) and moIL P-mercaptoethanol in a final concentration of 0.8% methylcellulose (Mithocel MC 4000 cP; Fluka AG, Buchs, Switzerland) in 6-well culture plates (Becton Dickinson Labware, Lincoln Park, NJ) containing different concentrations of the la,25(OH),D3 analogs. Cell concentrations were 1 X 10s/mL for AML blasts. After 10 days of incubation at 37°C in a humidified atmosphere containing 5% CO, in air, colonies (220 cells for HL-60 and 2 4 0 cells for fresh AML samples) were counted using an inverted microscope. All experiments were performed using triplicate plates per experimental point.
Cell surface murkers. Direct immunofluorescence for surfacemarker expression was studied under standard conditions. A quantity of 3 X 10' cells was incubated with a saturating concentration of the antibody for 45 minutes on ice. The HLA-DR antibody was fluorescein isothiocyanate (FITC)-labeled and obtained from Becton Dickinson (San JosC, CA); CD13 and CD38 antibodies were labeled with phycoerythrin (PE) and were also obtained from Becton Dickinson. Antibodies against CD1 lb and CD14 were purchased from Caltag (South San Francisco, CA) and labeled with PE and FITC, respectively. For all experiments, PE-or FITC-labeled isotype controls were used. Immunofluorescence was analyzed with a FACScan flow cytometer and analysis of data was performed with the Lysis11 software (Becton Dickinson, San Jose, CA).
Expression of WAFl/ClPl/p21. Sodium dodecyl sulfate-polyacrylamide gel electropheresis (SDS-PAGE) was performed as previously described." Briefly, extracts from 1.6 X IO6 cells were boiled in sample buffer (125 mmol/L Tris-HC1 [pH, 6.81, 1% SDS, 2% 0-mercaptoethanol, and 0.01% bromophenol blue) for 5 minutes and loaded onto a 10% SDS-polyacrylamide gel. After electrophoresis overnight at 45 V, the protein was transferred to Immobilon polyvinylidene difuride membrane (Millipore, Bedford, MA): blocked with 50 mmolL Tris-HC1 (pH, 7), 0.9% NaCl, 3% nonfat dry milk, and 0.05% Tween 20 for 4 hours; and then incubated overnight with the anti-WAFI/CIPl/p21 antibody from Pharmingen (San Diego, CA). The protein was detected using the enhanced chemiluminescence system from Amersham (Arlington Heights, IL). The intensity of the p21 band was scanned with a densitometer from Molecular Dynamics (Sunnyvale, CA). In case of unequal protein loading, the amount of p21 was normalized to the band obtained with an antibody to actin (AB1; Oncogene Sciences, Cambridge, MA).
Binding of 
RESULTS

Clonal inhibition of growth. All analogs of 1a,25
(OH)2D3 were tested in a dose-response fashion (lo"* to 10" mol&) and were found to be active in the clonal inhibition of HL-60 growth in soft agar. Dose-response curves were prepared (data not shown), and the concentration at which 50% of the colonies were inhibited (ED,,) by each analog is given in Table 1 . For all compounds, the ED50 ranges from to 2 X lo-" mom. Compared with the parental l~x,25(OH)~D~, 9 of I1 analogs achieved an EDSo at a 10-fold or lower concentration. The most potent analog examined for its ability to inhibit clonal growth of committed AML myeloid stem cells from three patients (Fig 2) . The mean EDso of analog LA and la,25(OH)2D3 was approximately 8 X 10"' mol& and m o m , respectively. Therefore, analog LA appeared to be approximately 125-fold more active than la,25(OH)zD3 on fresh leukemic colony-forming cells.
Induction of cell surface markers. The HLA-DR antigen as measured by fluorescent intensity was induced on the surface of HL-60 cells by all of the compounds mol/ L, 4 days; see (Table 2) . The parental l~x,25(OH)~D, induced the expression of HLA-DR (antigen density) by approximately 250%, and most of the analogs induced a comparable degree of expression of the antigen. The activation-and differentiation-related marker, CD1 Ib, was rather uniformly induced by all compounds on approximately 90% of the leukemic cells, and CD14 (receptor for lipopolysaccharide) was upregulated about 20-to 25-fold by each of the analogs use only. ( Table 2 ). The activation marker CD38 was only weakly induced by the parental compound [la,25(OH),D3] and by most of the analogs. The CD13 (aminopeptidase N) was strongly expressed on HL-60, and none of the 1a,25(OH)2D3 analogs had a major effect on expression of this antigen.
Induction of expression ofp21lWAFl. The CDKI known as WAFl/Cipl/p21 binds to the cyclin-dependent kinases (CDKs) to inhibit their a~tivities.'~-'~ All of the analogs of 1a,25(OH),D3, as well as the parental la,25(OH)zD3, induced expression of this CDKI by approximately twofold to ninefold (Figs 3 and 4, and Tables 2 and 3 ). The induction of WAF1 not only occurred at the highest concentration of vitamin D analogs tested mom), but also at lower concentrations: between mol& and lo-* mol&, no major difference was apparent (tested with the parent compound and analogs KR, KQ, KV, LA, and EO, data not shown). The 25-(OH),-22E,24E-diene-24-homo,26,27-F8 Table 3 for analogs KR and LA) and was also temporally related to the induction of the cell surface marker CD14 (data not shown).
DISCUSSION
This study demonstrated that nine of 11 newly synthesized analogs of la,25(OH)2D3 had a remarkable ability to inhibit The incorporation of two double bonds on the side chain (cmpd LA) appears further to increase activity. The RC1 of cmpd LA for VDR was 154% as measured by its ability to compete with ['HIla,25(OH)2D3 for binding to the VDR. This is one of the highest RCIvDR values reported to date for an analog, consistent with formation of a stable complex between the analog and the receptor.* The RCIDBp measures the relative ability of this compound to compete with 3H-1,25(OH)2D3 for binding to the DBP. The RCIDBp of cmpd LA is 9% of la,25(OH)2D3. Theoretically, this low RCIDBp increases its potency, because it is available to enter the cell, rather than remain in the serum bound to DBP. In fact, all of the analogs had lower RCIDBp values than did the parental la, 25 Relative band intensity of WAFlIpPl observed on Western blot as measured by densitometfy (see Fig 3) . Intensity of WAFl/p21 band in arbitrary units.
arbitrarily set at 100%.
I , has much less activity (EDSo, 1 X mol/L). Furthermore, the RCIvDR of this analog (KU) is 0.2%, compared with 31% and 100% for EO*." and lc1,25(OH)~D~ (Table l) , respectively.
Analog LG [25(OH)-I 6,23E-diene-26,27-Fh-DI]. which is missing the la-hydroxy, has an EDso of 3 X mol/L and a RCIvDR of 0.25%. So it has little ability to bind to the nuclear VDR compared with l0,25(0H)~D~; yet surprisingly, it is two to three times more potent than la,25(0H)?D3 in its inhibition of clonal growth. Furthermore, in recently concluded studies, we have found that this analog has little ability to inhibit clonogenic growth of the prostate cancer cell lines LNCaP and PC-3.*' Previously, we have shown that the 25(OH)*D3 is 1,OOO times less potent than la,25(OH)*D3 and has a RCIVDR of 2.4 Therefore, unlike 25(OH)D3, the unique structure of cmpd LG is able to compensate for its loss of the la-hydroxyl. One possible explanation of this increased activity is that the cells are able to lahydroxylate the analog. This hydroxylation is a specialized and specific enzymatic process, performed predominantly by cells in the kidney under careful feedback control. ' We have previously shown that the same process can occur in activated macrophage^.'^.^' However, we were unable to detect any la-hydroxylase activity in HL-60 cells.2' Another possibility is that this vitamin D3 analog can mediate its effects independent of the nuclear receptor for la,25(OH)*D3 (nVDR). Previously, we have reported that several la,25(OH)?D3 analogs can produce intracellular influxes of calcium within minutes of their exposure to the cells.30~3' This observation suggests that select analogs are inducing biologic changes in these cells in a fashion independent of VDWligand transactivation of target genes. Preliminary evidence has been obtained for a membrane receptor for l~r,25(OH)~D~ (mVDR)32; extensive studies support this concept that the ligand-binding domains of the nVDR and mVDR recognize different conformations of lc~,25(OH)~ ,25-(OH)2-16,23E-diene-26,27-bishomo-D3] , the latter group is 2.5-to fivefold more potent, suggesting the importance of the C-l6 ene and prominent potency even in the absence of the hexafluoride moiety. We previously have shown that hexafluoride-containing analogs (ie, cmpd LH and EO) produced hypercalcemia more readily than 1 ,25(OH)2D3 in mice." ' We and others have shown that the 20-epi-conformation of the la,25(OH)2D3 [20-epi-l ,25(OH)*D3, IE] markedly enhanced the potency of the vitamin D3 a n a l~g .~~" '~~' .~ We therefore constructed a l~x,25(OH)~D~ analog that also contained many of the structural motifs that have been shown in this study to be important [ 1(~,25-(OH)~-16,23E-diene- 26,27-F6-20-epi-D3, KY]; it had an EDso of 5 X 10"" mol/ L. This is no more potent than the analog EO (data not shown).16 In recent further studies with LNCaP human prostate cancer cells, we noted that the structural benefit gained by the 20-epi-conformation is lost by the addition of either the C-26,27 hexafluoride andor the C-l6 ene." Also, while studying clonal inhibition of prostate cancer cells by many of these same analogs, we have learned that the removal of C-l9 expanded the range of activities of the vitamin D7 analogs. 27 We therefore removed the C-l9 from analog EO [ la,25-(OH)2-16-ene-23-yne-26,27-F6-19-nor-D3, analog LH] and found that it had about the same potency to inhibit clonal growth of HL-60 cells as did cmpd EO (Table 2) .
Comparison of the RCIs provides some insight into structure-function of the analogs. Only one of the analogs (analog LA) binds to the VDR better than 1 (~, 2 5 ( 0 H )~D~; it is also the most potent analog. All of the other potent analogs bind the receptor up to 10-fold less avidly than 1a,25(OH)2D3, even though most of these compounds are 30-to 100-fold more potent than 1 C X ,~~( O H )~D~,
showing that the rank order of receptor affinity is not enough to explain the rank order of biologic effect of these analogs.
An interesting biologic and therapeutic question is whether cancer cells of different tissues display different sensitivities to vitamin D3 analogs. The answer appears to be yes. Concerning induction of cell surface antigens, the la, 25(OH)zD3 analogs, as well as the parental l~t,25(OH)~D,, induced expression of HLA-DR, CD14, and CDllb, and slightly enhanced expression of CD38. The induction of HLA-DR by the vitamin D, analogs is somewhat surprising and has not been reported to our knowledge. The HLA-DR is expressed on immature myeloid leukemic cells; mature myeloid cells have a low or absent expression of HLA-DR. In general, HLA-DR is also an activation marker present on stromal cells and T lymphocytes after their stimulation. The induction of HLA-DR may suggest that la,25(OH)zD3 and its analogs induce a discordant differentiation. Complete dose-response curves of the ability of vitamin D, analogs to modulate expression of these cell surface antigens were not done. Therefore, we are unable to comment on the potency of these analogs to induce expression of these markers of differentiation and cell activation.
The WAFl/CIPl/p21 is a CDKI that binds to most of the cyclin kinases and inhibits their action. Therefore, WAFl can act as a brake at many phases of the cell cycle. This CDKI is induced by ~53.4' However, others, as well as ourselves, have shown that WAFUp21 can be modulated independently of p53.19A8"0 In this study, induction of WAF1/ p21 by the la,25(OH)2D3 analogs occurred in p53-negative HL-60 cells, with expression of this CDKI increasing twofold to ninefold as discerned by Western blot. The induction of WAFl occurs early (by 24 to 48 hours) and persists during differentiation of HL-60 cells until day 4. Dose-response curves showed that the compounds tested here induce WAFl not only under the conditions of maximum differentiation ( mom), but also at lower, closer to pharmacologically achievable concentrations (lo" to lo-' mom). Two compounds (KR and LA) that are highly active for clonal inhibition, were also active at very low concentrations (down to 10"' mol/L) for induction of WAF1. Additionally, the kinetics of the induction of WAFl may be different in vitamin D analogs and la,25(OH) 2-D3. More work is necessary to correlate WAFl regulation, and the differentiating and antileukemic effects of the series of vitamin analogs studied here. Recently, another CDKI (~27~'p') was shown to be induced early by the parent compound 1,25(OH)2-D,, whereas in the same study, p21/WAFl was only transiently ele~ated.~' The reason for this discrepancy is unclear and may be related to culture conditions of the different studies. In addition, vitamin D analogs may utilize different pathways for cell-cycle control. CDKI may trigger the commitment to differentiation of HL-60 leukemic cells, either directly or through other molecules that are induced by vitamin D, compounds. We have previously shown that active phorbol diesters are able to stabilize the WAFl/p21 transcripts, perhaps leading to their increased availability for translati~n."~~~' To date, the mechanism by which vitamin D3 compounds induce WAFl/p21 has not been analyzed. The vitamin D3 analogs induce terminal differentiation of HL-60 toward nondividing, macrophage-like cells; this induction of differentiation may indirectly induce WAFl/p21, rather than have a direct effect of the vitamin D3 analogNDR complex on WAF1/ p21 transcription. Further studies are required.
This study has helped to decipher structural features that are important to increase the potency of the vitamin D3 analogs. At least for HL-60 cells, the more potent analogs have a C-l6 double bond and either a C-22, -23, or -24 double or triple bond. The most potent analog [LA, (22R)-la,25-(OH),-16,22,23-triene-D3] has the C-16, C-22, and C-23 double bonds incorporated into the parental 1,25(OH)2D3 structure. This appears more important than lengthening the side chain, adding fluorides, 20-epi-conformation, andor removal of C-l9 carbon. Furthermore, we showed that one of the most active compounds (LA) also markedly inhibited clonal growth of committed myeloid leukemic stem cells of patients. This study shows that many of these analogs merit a more thorough evaluation of their antileukemic activities in vivo.
